Literature DB >> 17635349

Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure.

M Torp1, L Brønd, N Hadrup, J B Nielsen, J Praetorius, S Nielsen, S Christensen, T E N Jonassen.   

Abstract

INTRODUCTION: Vasopressin (AVP) stimulates sodium reabsorption and Na,K,2Cl-cotransporter (NKCC2) protein level in the thick ascending limb (TAL) of Henle's loop in rats. Rats with congestive heart failure (CHF) have increased protein level of NKCC2, which can be normalized by angiotensin II receptor type-1 (AT(1)) blockade with losartan. AIM: In this study, we investigated whether CHF rats displayed changes in AVP stimulated cAMP formation in the TAL and examined the role of AT(1) receptor blockade on this system.
METHOD: CHF was induced by ligation of the left anterior descending coronary artery (LAD). SHAM-operated rats were used as controls. Half of the rats were treated with losartan (10 mg kg day(-1) i.p.).
RESULTS: CHF rats were characterized by increased left ventricular end diastolic pressure. Measurement of cAMP in isolated outer medullary TAL showed that both basal and AVP (10(-6) m) stimulated cAMP levels were significantly increased in CHF rats (25.52 +/- 4.49 pmol cAMP microg(-1) protein, P < 0.05) compared to Sham rats (8.13 +/- 1.14 pmol cAMP microg(-1) protein), P < 0.05). Losartan significantly reduced the basal level of cAMP in CHF rats (CHF: 12.56 +/- 1.93 fmol microg(-1) protein vs. Los-CHF: 7.49 +/- 1.08, P < 0.05), but not in Sham rats (SHAM: 4.66 +/- 0.59 vs. Los-SHAM: 4.75 +/- 0.71). AVP-mediated cAMP accumulation was absent in both groups treated with losartan (Los-SHAM: 4.75 +/- 0.71 and Los-CHF: 7.49 +/- 1.08).
CONCLUSION: The results indicate that the increased NKCC2 protein level in the mTAL from CHF rats is associated with increased cAMP accumulation in this segment. Furthermore, the finding that AT(1) receptor blockade prevents AVP-mediated cAMP accumulation in both SHAM and CHF rats suggests an interaction between angiotensin II and AVP in regulation of mTAL Na reabsorption.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635349     DOI: 10.1111/j.1748-1716.2007.01722.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  7 in total

1.  Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration.

Authors:  Weidong Wang; Chunling Li; Sandra Summer; Sandor Falk; Robert W Schrier
Journal:  Am J Physiol Renal Physiol       Date:  2010-06-24

2.  Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking.

Authors:  Chunling Li; Weidong Wang; Christopher J Rivard; Miguel A Lanaspa; Sandra Summer; Robert W Schrier
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-16

Review 3.  Ischemia and reactive oxygen species in sympathetic hyperactivity states: a vicious cycle that can be interrupted by renal denervation?

Authors:  Lisette E G Hubens; Willemien L Verloop; Jaap A Joles; Peter J Blankestijn; Michiel Voskuil
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

4.  Luminal angiotensin II stimulates rat medullary thick ascending limb chloride transport in the presence of basolateral norepinephrine.

Authors:  Michel Baum
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-09

5.  Water and sodium regulation in heart failure.

Authors:  Eun Hui Bae; Seong Kwon Ma
Journal:  Electrolyte Blood Press       Date:  2009-12-31

6.  AVP-induced increase in AQP2 and p-AQP2 is blunted in heart failure during cardiac remodeling and is associated with decreased AT1R abundance in rat kidney.

Authors:  Sophie Constantin Lütken; Jørgen Frøkiær; Søren Nielsen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 7.  Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.

Authors:  Ewa Szczepanska-Sadowska; Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.